To explore if SIRT3 SUMOylation-related pathways including upstream SENP1 and downstream HES1 can be targeted as potential therapeutic interventions against chemoresistance in AML, a combination of momordin-Ic, HES1 overexpression, and Ara-C was evaluated. This evidence concerns the gene SIRT3 and acute myeloid leukemia.